The 72 references in paper I. Leshchenko V., I. Baranova I., И. Лещенко В., И. Баранова И. (2014) “Биомаркеры воспаления при хронической обструктивной болезни легких // Inflammatory biomarkers in chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2012:i:2:p:108-117

1
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop repot Updated 2010. www.goldcopd.com
(check this in PDF content)
2
Seemungal T.A., Hurst J.R., Wedzicha J.A. Exacerbation rate, health status and mortality in COPD – a review of potential interventions. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 203–223.
(check this in PDF content)
3
Barnes P.J., Ito K., Adcock I.M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363: 731–733.
(check this in PDF content)
4
Vestbo J., Anderson W., Coxson H.O. et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE). Eur. Respir. J. 2008; 31: 869–873.
(check this in PDF content)
5
Celli B.R., Cote C.G., Marin J.M. et al. The body-mass index, airflow obstruction, dyspnoea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005–1012.
(check this in PDF content)
6
Rabe K.F., Hurd S., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532–555.
(check this in PDF content)
7
Celli B.R., MacNee W.,ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
(check this in PDF content)
8
Perng D.W., Huang H.Y., Chen H.M. et al. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest 2004; 126: 375–381.
(check this in PDF content)
9
Franciosi L.G., Page C.P., Celli B.R. et al.Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir. Res. 2006; 7: 74.
(check this in PDF content)
10
Barnes P.J., Chowdhury B., Kharitonov S.A. et al.Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 6–14.
(check this in PDF content)
11
Di Stefano A., Capelli A., Lusuardi M. et al.Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Respir. Crit. Care Med. 1998; 158: 1277–1285.
(check this in PDF content)
12
Gamble E., Grootendorst D.C., Brightling C.E. et al.Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 168: 976–982.
(check this in PDF content)
13
Hattotuwa K., Gamble E.A., O'Shaughnessy T. et al. Safety of bronchoscopy, biopsy, and BAL in research patients with COPD. Chest 2002; 122: 1909–1912.
(check this in PDF content)
14
Culpitt S.V., Rogers D.F., Shah P. et al.Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 24–31.
(check this in PDF content)
15
Pesci A., Balbi B., Majori M. et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1998; 12: 380–386.
(check this in PDF content)
16
Ekberg*Jansson A., Andersson B., Bake B. et al. Neutrophilassociated activation markers in healthy smokers relates to a fall in DL, CO and to emphysematous changes on high resolution CT. Respir. Med. 2001; 95: 363–373.
(check this in PDF content)
17
Tsoumakidou M., Tzanakis N., Siafakas N.M. Induced sputum in the investigation of airway inflammation of COPD. Respir. Med. 2003; 97: 863–871.
(check this in PDF content)
18
Taube C., Holz O., Mucke M. et al. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1810–1815.
(check this in PDF content)
19
Kelly M.M., Keatings V., Leigh R. et al.Analysis of fluidphase mediators. Eur. Respir. J. 2002; 20 (Suppl. 37): 24s–39s.
(check this in PDF content)
20
Kharitonov S.A., Barnes P.J.Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers 2002; 7: 1–32.
(check this in PDF content)
21
ATS / ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am. J. Respir. Crit. Care Med. 2005; 171: 912–930.
(check this in PDF content)
22
Bhowmik A., Seemungal T.A., Donaldson G.C., Wedzicha J.A. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur. Respir. J. 2005; 26: 1009–1015.
(check this in PDF content)
23
Paredi P., Kharitonov S.A., Leak D. et al. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 369–373.
(check this in PDF content)
24
Montuschi P., Barnes P.J. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol. Sci. 2002; 23: 232–237.
(check this in PDF content)
25
Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574–580.
(check this in PDF content)
26
Fanjul*Fernandez M., Folgueras A.R., Cabrera S. et al. Matrixmetalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 2010; 1803: 3–19.
(check this in PDF content)
27
Klein T., Bischoff R.Physiology and pathophysiology of matrixmetalloproteases. Amino Acids 2011; 41: 271–290.
(check this in PDF content)
28
Rodriguez D., Morrison C.J., Overall C.M.Matrix metalloproteinases:what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta 2010; 1803: 39–54.
(check this in PDF content)
29
Vanlaere I., Libert C. Matrix metalloproteinases as drug targets ininfections caused by gram-negative bacteria and in septic shock. Clin. Microbiol. Rev. 2009; 22: 224–239.
(check this in PDF content)
30
Dejonckheere E., Vandenbroucke R.E., Libert C. Matrix metalloproteinase-8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev. 2011; 22: 73–81.
(check this in PDF content)
31
Oikonomidi S., Kostikas K., Tsilioni I. et al. Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr. Med. Chem. 2009; 16: 1214–1228.
(check this in PDF content)
32
Baraldo S., Bazzan E., Zanin M.E. et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 2007; 132: 1733–1740.
(check this in PDF content)
33
Lim S., Roche N., Oliver B.G. et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am. J. Respir. Crit. Care Med. 2000; 162: 1355–1360.
(check this in PDF content)
34
Churg A., Dai J., Zay K. et al. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab. Invest. 2001; 81: 1119–1131.
(check this in PDF content)
35
Wagner P.D. Possible mechanisms underlying the development of cachexia in COPD. Eur. Respir. J. 2008; 31: 492–501.
(check this in PDF content)
36
Schols A.M., Broekhuizen R., Weling*Scheepers C.A. et al. Body composition and mortality in chronic obstructive pulmonary disease. Am. J. Clin. Nutr. 2005; 82: 53–59.
(check this in PDF content)
37
Debigare R., Cote C.H., Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am. J. Respir. Crit. Care Med. 2001; 164: 1712–1717.
(check this in PDF content)
38
Di Francia M., Barbier D., Mege J.L. et al. Tumor necrosis factoralpha levels and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1994; 150: 1453–1455.
(check this in PDF content)
39
Takabatake N., Nakamura H., Abe S. et al.Circulating leptin in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1215–1219.
(check this in PDF content)
40
Eid A.A., Ionescu A.A., Nixon L.S. et al.Inflammatory response and body composition in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1414–1418.
(check this in PDF content)
41
Itoh T., Nagaya N., Yoshikawa M. et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 879–882.
(check this in PDF content)
42
Broekhuizen R., Grimble R.F., Howell W.M. et al. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta-511 single nucleotide polymorphism. Am. J. Clin. Nutr. 2005; 82: 1059–1064.
(check this in PDF content)
43
Helvoort H.A., Heijdra Y.F., Thijs H.M. et al. Exerciseinduced systemic effects in muscle-wasted patients with COPD. Med. Sci. Sports Exerc. 2006; 38: 1543–1552.
(check this in PDF content)
44
Shin K.C., Chung J.H., Lee K.H.Effects of TNF-alpha and leptin on weight loss in patients with stable chronic obstructive pulmonary disease. Korean J. Intern. Med. 2007; 22: 249–255.
(check this in PDF content)
45
Kurosaki H., Ishii T., Motohashi N. et al. Extent of emphysema on HRCT affects loss of fat-free mass and fat mass in COPD. Intern. Med. 2009; 48: 41–48.
(check this in PDF content)
46
Eagan T.M.L., Aukrust P., Ueland T. et al. Body composition and plasma levels of inflammatory biomarkers in COPD. Eur. Respir. J. 2010; 36: 1027–1033.
(check this in PDF content)
47
Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165–1185.
(check this in PDF content)
48
Wouters E.F., Creutzberg E.C., Schols A.M.Systemic effects in COPD. Chest 2002; 121 (Suppl. 5): 127S–130S.
(check this in PDF content)
49
Broekhuizen R., Vernooy J.H., Schols A.M. et al. Leptin as local inflammatory marker in COPD. Respir. Med. 2005; 99: 70–74.
(check this in PDF content)
50
Bolton C.E., Ionescu A.A., Shiels K.M. et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 1286–1293.
(check this in PDF content)
51
Graat*Verboom L., Spruit M.A., van den Borne B.E. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component. Respir. Med. 2009; 103: 1143–1151.
(check this in PDF content)
52
Andreeva A.V., Kutuzov M.A., Voyno*Yasenetskaya T.A. Regulation of surfactant secretion in alveolar type II cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 293: L259–L271.
(check this in PDF content)
53
Dietl P., Haller T. Exocytosis of lung surfactant: from the secretory vesicle to the air-liquid interface. Ann. Rev. Physiol. 2005; 67: 595–621.
(check this in PDF content)
54
Wilder M.A. Surfactant protein B deficiency in infants with respiratory failure. J. Perinat. Neonatal. Nurs. 2004; 18: 61–67.
(check this in PDF content)
55
Kishore U., Bernal A.L., Kamran M.F. et al. Surfactant proteins SP-A and SP-D in human health and disease. Arch. Immunol. Ther. Exp. (Warsz) 2005; 53: 399–417.
(check this in PDF content)
56
Haczku A. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J. Allergy Clin. Immunol. 2008; 122: 861–879.
(check this in PDF content)
57
Pastva A.M., Walker J.K., Maddox L.A. et al.Nitric oxide mediates a relative airway hyporesponsiveness to lipopolysaccharide in surfactant protein-A deficient mice. Am. J. Respir. Cell. Mol. Biol. 2011; 44: 175–184.
(check this in PDF content)
58
Seppanen O., Glumoff V., Paananen R. et al.Transcription factors NF-kB and C/EBPd and IL-1-induced expression of surfactant protein A in lung explants during the perinatal period. Biol. Neonatal. 2005; 87: 152–159.
(check this in PDF content)
59
Shibata Y., Abe S., Inoue S. et al. Altered expression of antimicrobial molecules in cigarette smoke-exposed emphysematous mice lungs. Respirology 2008; 13: 1061–1065.
(check this in PDF content)
60
Beeh K.M., Beier J., Kornmann O. et al.Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest 2003; 123: 778–783.
(check this in PDF content)
61
Ohlmeier S., Vuolanto M., Toljamo T. et al. Proteomics of human lung tissue identifies surfactant protein A as a marker of chronic obstructive pulmonary disease. J. Prot. Res. 2008; 7: 5125–5132.
(check this in PDF content)
62
Kobayashi H., Kanoh S., Motoyoshi K.Serum surfactant protein-A, but not surfactant protein-D or KL-6, can predict preclinical lung damage induced by smoking. Biomarkers 2008; 13: 385–392.
(check this in PDF content)
63
Kishore U., Greenhough T.J., Waters P. et al.Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol. Immunol. 2006; 43: 1293–1315.
(check this in PDF content)
64
Sin D.D., Man S.F.P., Marciniuk D.D. et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 1207–1214.
(check this in PDF content)
65
Apweiler R., Aslanidis C., Deufel T. et al.Аpproaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin. Chem. Lab. Med. 2009; 47 (6): 724–744.
(check this in PDF content)
66
Ponten F., Gry M., Fagerberg L. et al.A global view of protein expression in human cells, tissues and organs. Mol. Sys. Biol. 2009. Epub ahead of print.
(check this in PDF content)
67
Sin D.D., Wu L., Anderson J.A., et al.Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992–997.
(check this in PDF content)
68
Lomas D.A., Silverman E.K., Edwards L.D. et al.Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur. Respir. J. 2009; 34: 95–102.
(check this in PDF content)
69
Cao Y., Grous M., Scanlon S.T. et al.The innate immune molecule surfactant protein (SP)-D is up regulated in the lung following cigarette smoke (CS) exposure in a murine model. Am. J. Respir. Crit. Care Med. 2004; 169: A832.
(check this in PDF content)
70
Sin D.D., Leung R., Gan W.Q. et al.Circulating surfactant protein D as a potential lung–specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm. Med. 2007; 7: 13.
(check this in PDF content)
71
Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–1121.
(check this in PDF content)
72
Celli B.R., Barnes P.J. Exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224–1238. Информация об авторах Лещенко Игорь Викторович– д. м. н., проф. кафедры пульмонологии и фтизиатрии ГБОУ ВПО "Уральская государственная медицинская
(check this in PDF content)